Free Trial
→ DOGE officially begins retirement transformation (From Altimetry) (Ad) Buy TARS Stock  Free TARS Stock Alerts

Tarsus Pharmaceuticals (TARS) Financials

Tarsus Pharmaceuticals logo
$46.43 +2.31 (+5.24%)
Closing price 04/11/2025 04:00 PM Eastern
Extended Trading
$46.44 +0.02 (+0.03%)
As of 04/11/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Tarsus Pharmaceuticals

Annual Income Statements for Tarsus Pharmaceuticals

This table shows Tarsus Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -4.67 -27 -14 -62 -136 -116
Consolidated Net Income / (Loss)		 -4.67 -27 -14 -62 -136 -116
Net Income / (Loss) Continuing Operations		 -4.67 -27 -14 -62 -136 -116
Total Pre-Tax Income 		-4.67 -27 -14 -62 -136 -116
Total Operating Income		 -4.30 -27 -12 -63 -143 -121
Total Gross Profit		 0.00 0.00 55 25 16 170
Total Revenue		 0.00 0.00 57 26 17 183
Operating Revenue		 - 0.00 57 26 17 183
Total Cost of Revenue		 0.00 0.00 2.08 0.96 1.59 13
Operating Cost of Revenue		 - 0.00 2.08 0.96 1.59 13
Total Operating Expenses		 4.30 27 67 88 159 291
Selling, General & Admin Expense		 1.14 8.17 25 45 109 237
Research & Development Expense		 3.16 19 42 43 50 53
Total Other Income / (Expense), net		 -0.37 0.19 -1.62 0.62 7.27 5.02
Interest Expense		 0.26 - 0.00 2.20 3.35 9.79
Interest & Investment Income		 -0.04 0.19 0.04 3.50 10 15
Other Income / (Expense), net		 -0.08 0.00 -1.65 -0.68 0.27 -0.21
Income Tax Expense		 0.00 0.00 0.06 -0.00 0.00 0.00
Basic Earnings per Share		 ($1.98) ($4.32) ($0.67) ($2.52) ($4.62) ($3.07)
Weighted Average Basic Shares Outstanding		 2.36M 6.21M 20.55M 24.62M 29.38M 37.60M
Diluted Earnings per Share		 ($1.98) ($4.32) ($0.67) ($2.52) ($4.62) ($3.07)
Weighted Average Diluted Shares Outstanding		 2.36M 6.21M 20.55M 24.62M 29.38M 37.60M
Weighted Average Basic & Diluted Shares Outstanding		 2.36M 6.21M 20.71M 26.73M 34.22M 38.38M
Cash Dividends to Common per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00

Quarterly Income Statements for Tarsus Pharmaceuticals

This table shows Tarsus Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -23 -14 -23 -31 -39 -42 -36 -33 -23 -23
Consolidated Net Income / (Loss)		 -23 -14 -23 -31 -39 -42 -36 -33 -23 -23
Net Income / (Loss) Continuing Operations		 -23 -14 -23 -31 -39 -42 -36 -33 -23 -23
Total Pre-Tax Income 		-23 -14 -23 -31 -39 -42 -36 -33 -23 -23
Total Operating Income		 -23 -15 -25 -33 -41 -44 -38 -33 -25 -24
Total Gross Profit		 0.00 9.60 2.50 0.00 1.49 12 26 38 45 61
Total Revenue		 0.00 10 2.50 0.00 1.87 13 28 41 48 66
Operating Revenue		 0.00 10 2.50 0.00 1.87 13 28 41 48 66
Total Cost of Revenue		 0.00 0.40 0.00 0.00 0.38 1.22 1.65 3.00 3.24 4.93
Operating Cost of Revenue		 0.00 0.40 0.00 0.00 0.38 1.22 1.65 3.00 3.24 4.93
Total Operating Expenses		 23 25 27 33 42 56 64 71 70 86
Selling, General & Admin Expense		 12 15 15 20 30 43 52 59 58 69
Research & Development Expense		 11 10 12 13 12 13 12 12 12 17
Total Other Income / (Expense), net		 0.39 1.46 1.53 1.40 1.79 2.55 1.95 0.01 1.74 1.31
Interest Expense		 0.63 0.71 0.68 0.82 0.86 0.99 0.98 4.05 2.45 2.31
Interest & Investment Income		 1.06 2.14 2.29 2.23 2.84 2.98 3.12 4.13 4.12 3.65
Other Income / (Expense), net		 -0.04 0.03 -0.08 -0.01 -0.20 0.56 -0.18 -0.07 0.07 -0.03
Basic Earnings per Share		 ($0.84) ($0.46) ($0.88) ($1.17) ($1.28) ($1.29) ($1.01) ($0.88) ($0.61) ($0.57)
Weighted Average Basic Shares Outstanding		 26.66M 24.62M 26.74M 26.82M 30.62M 29.38M 35.30M 37.82M 38.38M 37.60M
Diluted Earnings per Share		 ($0.84) ($0.46) ($0.88) ($1.17) ($1.28) ($1.29) ($1.01) ($0.88) ($0.61) ($0.57)
Weighted Average Diluted Shares Outstanding		 26.66M 24.62M 26.74M 26.82M 30.62M 29.38M 35.30M 37.82M 38.38M 37.60M
Weighted Average Basic & Diluted Shares Outstanding		 26.67M 26.73M 26.80M 32.62M 33.10M 34.22M 37.78M 38.04M 38.23M 38.38M

Annual Cash Flow Statements for Tarsus Pharmaceuticals

This table details how cash moves in and out of Tarsus Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 56 110 3.18 -100 153 -128
Net Cash From Operating Activities		 -3.67 -21 3.75 -49 -117 -83
Net Cash From Continuing Operating Activities		 -3.67 -21 3.75 -49 -118 -83
Net Income / (Loss) Continuing Operations		 -4.67 -27 -14 -62 -136 -116
Consolidated Net Income / (Loss)		 -4.67 -27 -14 -62 -136 -116
Depreciation Expense		 0.04 0.10 0.31 0.33 0.74 0.69
Amortization Expense		 0.04 - 0.00 -1.01 -2.65 -3.19
Non-Cash Adjustments To Reconcile Net Income		 0.44 4.12 16 15 20 31
Changes in Operating Assets and Liabilities, net		 0.49 1.46 1.37 -0.95 0.31 3.84
Net Cash From Investing Activities		 -0.18 -0.46 -0.59 -145 141 -199
Net Cash From Continuing Investing Activities		 -0.18 -0.46 -0.59 -145 141 -199
Purchase of Property, Plant & Equipment		 -0.18 -0.46 -0.59 -0.51 -1.50 -1.57
Acquisitions		 - - - 0.00 -4.00 -5.00
Purchase of Investments		 - - 0.00 -149 -29 -266
Sale and/or Maturity of Investments		 - - 0.00 5.32 175 73
Net Cash From Financing Activities		 59 132 0.02 94 130 155
Net Cash From Continuing Financing Activities		 59 132 0.02 94 130 155
Repayment of Debt		 - - 0.00 -0.88 0.00 -35
Issuance of Debt		 1.99 - - 20 10 75
Issuance of Common Equity		 0.17 92 0.22 75 120 109
Other Financing Activities, net		 0.00 0.37 -0.20 0.05 0.59 5.61
Cash Interest Paid		 - - 0.00 1.68 2.88 7.66

Quarterly Cash Flow Statements for Tarsus Pharmaceuticals

This table details how cash moves in and out of Tarsus Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -76 -98 -5.66 41 120 -1.73 -31 -13 -4.89 -79
Net Cash From Operating Activities		 -19 -11 -22 -24 -32 -39 -38 -14 -8.65 -22
Net Cash From Continuing Operating Activities		 -19 -11 -22 -24 -32 -40 -38 -14 -8.74 -22
Net Income / (Loss) Continuing Operations		 -23 -14 -23 -31 -39 -42 -36 -33 -23 -23
Consolidated Net Income / (Loss)		 -23 -14 -23 -31 -39 -42 -36 -33 -23 -23
Depreciation Expense		 0.09 0.10 0.10 0.18 0.21 0.25 0.17 0.14 0.18 0.19
Amortization Expense		 0.03 -1.18 -1.40 -0.98 -0.39 0.12 -0.08 -1.10 -0.92 -1.10
Non-Cash Adjustments To Reconcile Net Income		 3.73 3.72 4.12 5.31 5.52 4.76 6.31 9.81 7.50 7.57
Changes in Operating Assets and Liabilities, net		 0.04 0.09 -1.41 3.12 1.41 -2.81 -8.59 10 7.91 -5.73
Net Cash From Investing Activities		 -57 -87 11 64 47 18 -102 -41 3.13 -60
Net Cash From Continuing Investing Activities		 -57 -87 11 64 47 18 -102 -41 3.13 -60
Purchase of Property, Plant & Equipment		 -0.10 -0.13 -0.34 -0.79 -0.38 - -0.17 -1.04 -0.28 -0.07
Acquisitions		 - - - - - - - - - -5.00
Purchase of Investments		 -57 -92 -29 - 0.00 - -105 -50 -21 -90
Sale and/or Maturity of Investments		 - 5.32 40 65 52 18 2.50 11 24 35
Net Cash From Financing Activities		 -0.14 0.26 5.01 0.51 105 20 109 42 0.64 2.93
Net Cash From Continuing Financing Activities		 -0.14 0.26 5.01 0.51 105 20 109 42 0.64 2.93
Issuance of Common Equity		 -0.14 0.14 0.01 0.51 100 19 109 2.68 0.68 -2.68
Cash Interest Paid		 0.97 0.58 0.59 0.71 0.73 0.85 0.87 0.47 4.15 2.17

Annual Balance Sheets for Tarsus Pharmaceuticals

This table presents Tarsus Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 58 172 179 228 265 377
Total Current Assets		 58 171 176 225 256 357
Cash & Equivalents		 58 168 171 72 225 95
Short-Term Investments		 - - 0.48 145 2.50 197
Accounts Receivable		 0.04 0.02 0.09 3.58 18 48
Inventories, net		 - - - 0.00 3.11 2.62
Prepaid Expenses		 0.02 2.49 4.05 4.77 7.87 15
Plant, Property, & Equipment, net		 0.15 0.55 0.76 0.96 1.47 2.31
Total Noncurrent Assets		 0.13 0.77 2.20 1.53 7.89 18
Long-Term Investments		 - - 0.00 0.37 0.63 3.00
Intangible Assets		 - - - 0.00 3.87 8.33
Other Noncurrent Operating Assets		 0.13 0.77 2.20 1.16 3.39 6.65
Total Liabilities & Shareholders' Equity		 58 172 179 228 265 377
Total Liabilities		 0.92 5.99 12 35 69 152
Total Current Liabilities		 0.82 5.39 11 15 37 81
Accounts Payable		 0.52 4.35 8.68 9.91 24 65
Current Employee Benefit Liabilities		 0.30 1.04 2.80 5.52 13 16
Total Noncurrent Liabilities		 0.10 0.61 0.70 20 32 72
Long-Term Debt		 - - 0.00 19 30 72
Other Noncurrent Operating Liabilities		 0.10 0.61 0.70 0.10 1.75 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -6.01 166 167 193 197 225
Total Preferred & Common Equity		 -6.01 166 167 193 197 225
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -6.01 166 167 193 197 225
Common Stock		 0.03 199 213 302 442 585
Retained Earnings		 -6.03 -33 -47 -109 -245 -360
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.07 -0.00 0.18

Quarterly Balance Sheets for Tarsus Pharmaceuticals

This table presents Tarsus Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 236 211 189 268 349 377 376
Total Current Assets		 234 209 183 259 341 363 357
Cash & Equivalents		 169 66 107 227 194 181 176
Short-Term Investments		 57 135 71 20 105 142 141
Accounts Receivable		 4.01 2.92 0.25 6.37 31 31 30
Inventories, net		 - - - 0.02 4.04 2.20 2.85
Prepaid Expenses		 3.49 4.51 5.00 6.01 6.80 5.97 7.02
Plant, Property, & Equipment, net		 0.95 1.19 1.54 1.61 1.34 2.24 2.39
Total Noncurrent Assets		 1.44 1.38 3.91 7.44 7.22 9.48 17
Long-Term Investments		 0.16 0.31 0.32 0.21 0.00 3.00 3.00
Intangible Assets		 - - - 3.97 3.77 3.67 8.57
Other Noncurrent Operating Assets		 1.28 1.07 3.59 3.26 3.45 2.82 5.22
Total Liabilities & Shareholders' Equity		 236 211 189 268 349 377 376
Total Liabilities		 34 38 41 55 74 125 139
Total Current Liabilities		 14 13 15 23 43 52 66
Accounts Payable		 10 9.05 9.46 15 37 44 55
Current Employee Benefit Liabilities		 4.09 4.21 5.31 7.90 5.96 8.05 11
Total Noncurrent Liabilities		 20 25 26 31 32 73 73
Long-Term Debt		 19 25 25 30 30 72 72
Other Noncurrent Operating Liabilities		 0.21 0.04 1.83 1.71 1.61 1.45 1.24
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 203 173 148 214 275 252 237
Total Preferred & Common Equity		 203 173 148 214 275 252 237
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 203 173 148 214 275 252 237
Common Stock		 298 306 311 416 556 566 574
Retained Earnings		 -95 -132 -164 -203 -280 -314 -337
Accumulated Other Comprehensive Income / (Loss)		 -0.01 -0.07 -0.02 -0.01 -0.06 -0.18 0.35

Annual Metrics and Ratios for Tarsus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Tarsus Pharmaceuticals' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -54.73% -32.42% 948.62%
EBITDA Growth		 0.00% -525.63% 49.83% -374.78% -125.96% 14.85%
EBIT Growth		 0.00% -517.24% 48.86% -359.12% -125.39% 15.47%
NOPAT Growth		 0.00% -528.15% 54.97% -415.85% -128.28% 15.78%
Net Income Growth		 0.00% -474.11% 48.43% -349.06% -118.86% 14.97%
EPS Growth		 0.00% -118.18% 84.49% -276.12% -83.33% 33.55%
Operating Cash Flow Growth		 0.00% -475.50% 117.73% -1,408.16% -139.63% 29.33%
Free Cash Flow Firm Growth		 0.00% 0.00% 67.67% -685.15% -136.81% 15.71%
Invested Capital Growth		 0.00% -277.22% -134.44% 0.43% 75.00% 258.21%
Revenue Q/Q Growth		 0.00% 0.00% 0.60% 59.81% 21.40% 41.14%
EBITDA Q/Q Growth		 0.00% 0.00% -32.80% -2.14% -23.36% 12.84%
EBIT Q/Q Growth		 0.00% 0.00% -31.82% -0.36% -25.31% 13.87%
NOPAT Q/Q Growth		 0.00% 0.00% -32.36% -0.99% -25.83% 14.25%
Net Income Q/Q Growth		 0.00% 0.00% -32.42% 1.98% -26.31% 13.99%
EPS Q/Q Growth		 0.00% 0.00% -149.26% 7.69% -21.90% 19.00%
Operating Cash Flow Q/Q Growth		 0.00% -77.17% -36.00% 2.48% -31.97% 17.12%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -1.24% -28.94% 4.06%
Invested Capital Q/Q Growth		 0.00% 0.00% -9.14% -6.68% 66.00% 118.62%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 96.36% 96.30% 90.87% 92.99%
EBITDA Margin		 0.00% 0.00% -23.67% -248.20% -829.86% -67.38%
Operating Margin		 0.00% 0.00% -21.32% -242.92% -820.53% -65.90%
EBIT Margin		 0.00% 0.00% -24.21% -245.56% -818.96% -66.01%
Profit (Net Income) Margin		 0.00% 0.00% -24.25% -240.51% -778.89% -63.16%
Tax Burden Percent		 100.02% 100.00% 100.40% 99.99% 100.00% 100.00%
Interest Burden Percent		 106.74% 99.30% 99.74% 97.95% 95.11% 95.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -22,903.20%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -22,888.39%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 22,848.38%
Return on Equity (ROE)		 -8.14% -24.01% -8.31% -34.53% -69.71% -54.83%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -4,376.80%
Operating Return on Assets (OROA)		 0.00% 0.00% -7.87% -31.17% -57.92% -37.60%
Return on Assets (ROA)		 0.00% 0.00% -7.88% -30.53% -55.09% -35.97%
Return on Common Equity (ROCE)		 0.85% -17.19% -8.31% -34.53% -69.71% -54.83%
Return on Equity Simple (ROE_SIMPLE)		 77.77% -16.15% -8.29% -32.19% -68.99% -51.46%
Net Operating Profit after Tax (NOPAT)		 -3.01 -19 -8.51 -44 -100 -84
NOPAT Margin		 0.00% 0.00% -14.92% -170.04% -574.37% -46.13%
Net Nonoperating Expense Percent (NNEP)		 -2.87% -7.00% -3.13% -9.84% -18.01% -14.81%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -20.67% -44.18% -28.48%
Cost of Revenue to Revenue		 0.00% 0.00% 3.64% 3.70% 9.13% 7.01%
SG&A Expenses to Revenue		 0.00% 0.00% 44.54% 174.11% 623.03% 129.71%
R&D to Revenue		 0.00% 0.00% 73.14% 165.11% 288.37% 29.18%
Operating Expenses to Revenue		 0.00% 0.00% 117.68% 339.22% 911.40% 158.89%
Earnings before Interest and Taxes (EBIT)		 -4.37 -27 -14 -63 -143 -121
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.30 -27 -13 -64 -145 -123
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 5.06 2.79 2.03 3.40 9.43
Price to Tangible Book Value (P/TBV)		 0.00 5.06 2.79 2.03 3.47 9.79
Price to Revenue (P/Rev)		 0.00 0.00 8.16 15.15 38.42 11.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 945.63
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 5.15 7.48 27.06 10.35
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 78.29 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.10 0.15 0.32
Long-Term Debt to Equity		 0.00 0.00 0.00 0.10 0.15 0.32
Financial Leverage		 -1.01 -1.01 -1.02 -1.03 -1.02 -1.00
Leverage Ratio		 1.02 1.03 1.05 1.13 1.27 1.52
Compound Leverage Factor		 1.08 1.02 1.05 1.11 1.20 1.46
Debt to Total Capital		 0.00% 0.00% 0.00% 9.15% 13.15% 24.24%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 9.15% 13.15% 24.24%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 110.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -10.46% 100.00% 100.00% 90.85% 86.85% 75.76%
Debt to EBITDA		 0.00 0.00 0.00 -0.30 -0.21 -0.58
Net Debt to EBITDA		 0.00 0.00 0.00 3.09 1.37 1.81
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.30 -0.21 -0.58
Debt to NOPAT		 0.00 0.00 0.00 -0.44 -0.30 -0.85
Net Debt to NOPAT		 0.00 0.00 0.00 4.51 1.98 2.64
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.44 -0.30 -0.85
Altman Z-Score		 53.02 84.46 23.73 6.34 3.86 7.30
Noncontrolling Interest Sharing Ratio		 110.46% 28.38% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 70.85 31.68 15.33 14.61 6.93 4.43
Quick Ratio		 70.80 31.21 14.98 14.30 6.64 4.21
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -17 -5.59 -44 -104 -88
Operating Cash Flow to CapEx		 -2,098.86% -4,635.53% 639.59% -9,689.72% -7,822.44% -5,298.47%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -19.97 -31.08 -8.95
Operating Cash Flow to Interest Expense		 -14.40 0.00 0.00 -22.30 -35.11 -8.48
Operating Cash Flow Less CapEx to Interest Expense		 -15.09 0.00 0.00 -22.53 -35.56 -8.64
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.33 0.13 0.07 0.57
Accounts Receivable Turnover		 0.00 0.00 1,018.34 14.05 1.64 5.56
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 4.48
Fixed Asset Turnover		 0.00 0.00 87.53 30.16 14.39 96.75
Accounts Payable Turnover		 0.00 0.00 0.32 0.10 0.09 0.29
Days Sales Outstanding (DSO)		 0.00 0.00 0.36 25.97 222.76 65.61
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 81.49
Days Payable Outstanding (DPO)		 0.00 0.00 1,145.75 3,552.54 3,849.46 1,258.97
Cash Conversion Cycle (CCC)		 0.00 0.00 -1,145.39 -3,526.57 -3,626.69 -1,111.87
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.58 -2.17 -5.09 -5.06 -1.27 2.00
Invested Capital Turnover		 0.00 0.00 -15.72 -5.09 -5.51 496.48
Increase / (Decrease) in Invested Capital		 0.00 -1.59 -2.92 0.02 3.80 3.27
Enterprise Value (EV)		 85 672 293 193 472 1,894
Market Capitalization		 80 840 465 391 670 2,117
Book Value per Share		 ($2.54) $8.17 $8.06 $7.23 $5.95 $5.87
Tangible Book Value per Share		 ($2.54) $8.17 $8.06 $7.23 $5.83 $5.66
Total Capital		 57 166 167 212 227 296
Total Debt		 0.00 0.00 0.00 19 30 72
Total Long-Term Debt		 0.00 0.00 0.00 19 30 72
Net Debt		 -58 -168 -172 -198 -198 -223
Capital Expenditures (CapEx)		 0.18 0.46 0.59 0.51 1.50 1.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.76 -2.88 -7.34 -7.08 -8.25 -15
Debt-free Net Working Capital (DFNWC)		 57 165 164 210 219 276
Net Working Capital (NWC)		 57 165 164 210 219 276
Net Nonoperating Expense (NNE)		 1.66 7.91 5.32 18 36 31
Net Nonoperating Obligations (NNO)		 -58 -168 -172 -198 -198 -223
Total Depreciation and Amortization (D&A)		 0.07 0.10 0.31 -0.68 -1.90 -2.51
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -12.87% -27.42% -47.27% -8.35%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 288.41% 813.24% 1,256.35% 150.91%
Net Working Capital to Revenue		 0.00% 0.00% 288.41% 813.24% 1,256.35% 150.91%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.32) ($0.67) ($2.52) ($4.62) ($3.07)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 20.50M 20.55M 24.62M 29.38M 37.60M
Adjusted Diluted Earnings per Share		 $0.00 ($4.32) ($0.67) ($2.52) ($4.62) ($3.07)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 20.50M 20.55M 24.62M 29.38M 37.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.32) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 6.21M 20.71M 26.73M 34.22M 38.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.01 -19 -8.51 -44 -100 -84
Normalized NOPAT Margin		 0.00% 0.00% -14.92% -170.04% -574.37% -46.13%
Pre Tax Income Margin		 0.00% 0.00% -24.15% -240.53% -778.89% -63.16%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -17.15 0.00 0.00 -28.83 -42.70 -12.33
NOPAT to Interest Expense		 -11.80 0.00 0.00 -19.96 -29.95 -8.62
EBIT Less CapEx to Interest Expense		 -17.84 0.00 0.00 -29.06 -43.15 -12.49
NOPAT Less CapEx to Interest Expense		 -12.48 0.00 0.00 -20.19 -30.40 -8.78
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Tarsus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Tarsus Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -100.00% 2,858.58% 363.82% -100.00% 0.00% 30.76% 1,004.56% 0.00% 2,471.78% 407.86%
EBITDA Growth		 -42.95% -9.08% -32.80% -531.87% -81.01% -170.17% -43.47% -2.07% 37.47% 41.74%
EBIT Growth		 -42.99% -1.52% -25.64% -497.43% -79.26% -191.94% -51.29% -1.62% 38.99% 44.30%
NOPAT Growth		 -45.85% -4.24% -27.82% -528.27% -78.71% -195.13% -51.03% -1.47% 38.53% 45.06%
Net Income Growth		 -43.41% 8.43% -15.72% -447.17% -73.91% -208.13% -52.57% -5.94% 40.18% 44.84%
EPS Growth		 -10.53% 31.34% 10.20% -387.50% -52.38% -180.43% -14.77% 24.79% 52.34% 55.81%
Operating Cash Flow Growth		 -361.68% 10.29% -43.73% -459.43% -73.89% -261.73% -72.00% 39.55% 73.26% 43.61%
Free Cash Flow Firm Growth		 -116.87% -46.78% -202.43% -227.79% -86.10% -230.46% -76.12% -12.59% 64.36% 41.67%
Invested Capital Growth		 -1.87% 0.43% 47.92% -30.41% 21.56% 75.00% 283.58% 14.89% -189.01% 258.21%
Revenue Q/Q Growth		 -100.00% 0.00% -75.00% -100.00% 0.00% 598.88% 111.18% 47.80% 17.90% 38.01%
EBITDA Q/Q Growth		 -328.77% 29.40% -63.41% -27.73% -22.83% -5.37% 13.29% 9.12% 24.76% 1.81%
EBIT Q/Q Growth		 -317.47% 34.48% -66.48% -31.19% -25.26% -6.71% 13.73% 11.88% 24.79% 2.58%
NOPAT Q/Q Growth		 -338.48% 34.25% -65.67% -31.54% -24.72% -8.59% 15.22% 11.63% 24.44% 2.94%
Net Income Q/Q Growth		 -291.97% 39.59% -72.21% -34.18% -24.58% -7.03% 14.73% 6.83% 29.65% 1.31%
EPS Q/Q Growth		 -250.00% 45.24% -91.30% -32.95% -9.40% -0.78% 21.71% 12.87% 30.68% 6.56%
Operating Cash Flow Q/Q Growth		 -336.98% 41.57% -102.04% -8.45% -35.83% -21.55% 3.93% 61.88% 39.93% -156.38%
Free Cash Flow Firm Q/Q Growth		 -194.67% 33.75% -96.73% -3.57% -37.87% -17.64% -4.85% 33.79% 56.36% -92.54%
Invested Capital Q/Q Growth		 0.40% -6.68% 28.78% -72.32% 40.09% 66.00% 622.91% -179.89% -103.44% 118.62%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 96.00% 100.00% 0.00% 79.85% 90.70% 94.01% 92.64% 93.26% 92.58%
EBITDA Margin		 0.00% -161.10% -1,053.08% 0.00% -2,207.64% -332.86% -136.78% -84.10% -53.67% -38.19%
Operating Margin		 0.00% -150.61% -998.08% 0.00% -2,187.87% -339.94% -136.47% -81.60% -52.29% -36.77%
EBIT Margin		 0.00% -150.34% -1,001.12% 0.00% -2,198.29% -335.66% -137.12% -81.76% -52.15% -36.81%
Profit (Net Income) Margin		 0.00% -135.99% -936.76% 0.00% -2,092.36% -320.45% -129.39% -81.57% -48.67% -34.80%
Tax Burden Percent		 99.98% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.13% 90.46% 93.57% 95.70% 95.18% 95.47% 94.36% 99.77% 93.33% 94.54%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,697.89% 0.00% 0.00% -12,780.36%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,693.69% 0.00% 0.00% -12,777.50%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,675.60% 0.00% 0.00% 12,755.16%
Return on Equity (ROE)		 -33.18% -34.53% -40.47% -49.27% -51.69% -69.71% -22.30% -75.04% -59.56% -25.20%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,802.86% 0.00% 0.00% -4,376.80%
Operating Return on Assets (OROA)		 0.00% -19.08% -141.63% 0.00% -125.17% -23.74% -20.82% -24.10% -20.97% -20.97%
Return on Assets (ROA)		 0.00% -17.26% -132.52% 0.00% -119.13% -22.66% -19.65% -24.04% -19.57% -19.82%
Return on Common Equity (ROCE)		 -33.18% -34.53% -40.47% -49.27% -51.69% -69.71% -22.30% -75.04% -59.56% -25.20%
Return on Equity Simple (ROE_SIMPLE)		 -31.26% 0.00% -37.64% -61.57% -50.35% 0.00% -53.85% -59.49% -56.57% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -11 -17 -23 -29 -31 -26 -23 -18 -17
NOPAT Margin		 0.00% -105.43% -698.66% 0.00% -1,531.51% -237.96% -95.53% -57.12% -36.60% -25.74%
Net Nonoperating Expense Percent (NNEP)		 -3.31% -1.65% -3.57% -4.44% -4.94% -5.45% -4.20% -4.85% -2.49% -2.86%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.97% - - - -13.72% - - - -5.77%
Cost of Revenue to Revenue		 0.00% 4.00% 0.00% 0.00% 20.15% 9.30% 5.99% 7.36% 6.74% 7.42%
SG&A Expenses to Revenue		 0.00% 146.33% 603.84% 0.00% 1,620.74% 328.89% 186.78% 144.05% 120.35% 103.95%
R&D to Revenue		 0.00% 100.28% 494.24% 0.00% 646.98% 101.75% 43.70% 30.18% 25.20% 25.41%
Operating Expenses to Revenue		 0.00% 246.61% 1,098.08% 0.00% 2,267.72% 430.64% 230.48% 174.24% 145.55% 129.36%
Earnings before Interest and Taxes (EBIT)		 -23 -15 -25 -33 -41 -44 -38 -33 -25 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -16 -26 -34 -41 -44 -38 -34 -26 -25
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.25 2.03 1.94 3.28 2.71 3.40 4.37 4.07 5.27 9.43
Price to Tangible Book Value (P/TBV)		 2.25 2.03 1.94 3.28 2.76 3.47 4.43 4.13 5.47 9.79
Price to Revenue (P/Rev)		 28.25 15.15 12.10 38.75 40.33 38.42 28.27 12.32 9.65 11.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 141.20 0.00 0.00 945.63
Enterprise Value to Revenue (EV/Rev)		 15.42 7.48 5.72 26.43 25.20 27.06 21.96 9.26 7.74 10.35
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.10 0.10 0.14 0.17 0.14 0.15 0.11 0.28 0.30 0.32
Long-Term Debt to Equity		 0.10 0.10 0.14 0.17 0.14 0.15 0.11 0.28 0.30 0.32
Financial Leverage		 -1.02 -1.03 -1.03 -1.03 -1.02 -1.02 -0.99 -1.03 -1.03 -1.00
Leverage Ratio		 1.12 1.13 1.22 1.20 1.21 1.27 1.25 1.41 1.43 1.52
Compound Leverage Factor		 1.10 1.02 1.14 1.15 1.15 1.21 1.18 1.41 1.33 1.44
Debt to Total Capital		 8.72% 9.15% 12.39% 14.28% 12.21% 13.15% 9.81% 22.10% 23.19% 24.24%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 8.72% 9.15% 12.39% 14.28% 12.21% 13.15% 9.81% 22.10% 23.19% 24.24%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.28% 90.85% 87.61% 85.72% 87.79% 86.85% 90.19% 77.90% 76.81% 75.76%
Debt to EBITDA		 -0.31 -0.30 -0.35 -0.25 -0.25 -0.21 -0.19 -0.46 -0.51 -0.58
Net Debt to EBITDA		 3.31 3.09 2.51 1.56 1.85 1.37 1.72 1.63 1.76 1.81
Long-Term Debt to EBITDA		 -0.31 -0.30 -0.35 -0.25 -0.25 -0.21 -0.19 -0.46 -0.51 -0.58
Debt to NOPAT		 -0.45 -0.44 -0.51 -0.37 -0.37 -0.30 -0.27 -0.65 -0.73 -0.85
Net Debt to NOPAT		 4.77 4.51 3.71 2.30 2.73 1.98 2.46 2.33 2.52 2.64
Long-Term Debt to NOPAT		 -0.45 -0.44 -0.51 -0.37 -0.37 -0.30 -0.27 -0.65 -0.73 -0.85
Altman Z-Score		 8.39 7.04 5.31 6.41 5.91 5.09 9.41 4.70 5.21 8.14
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 16.40 14.61 15.74 12.43 11.15 6.93 8.01 7.03 5.42 4.43
Quick Ratio		 16.16 14.30 15.40 12.09 10.89 6.64 7.76 6.87 5.27 4.21
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -11 -21 -22 -30 -35 -37 -24 -11 -20
Operating Cash Flow to CapEx		 -19,386.46% -8,562.20% -6,461.76% -3,027.45% -8,629.87% 0.00% -21,717.82% -1,382.34% -3,101.08% -30,808.33%
Free Cash Flow to Firm to Interest Expense		 -25.19 -14.96 -30.39 -26.41 -34.59 -35.30 -37.24 -5.98 -4.33 -8.81
Operating Cash Flow to Interest Expense		 -29.40 -15.40 -32.12 -29.23 -37.72 -39.77 -38.44 -3.55 -3.54 -9.59
Operating Cash Flow Less CapEx to Interest Expense		 -29.55 -15.58 -32.62 -30.20 -38.16 -39.77 -38.62 -3.81 -3.65 -9.63
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.08 0.13 0.14 0.06 0.06 0.07 0.15 0.29 0.40 0.57
Accounts Receivable Turnover		 7.78 14.05 17.14 28.87 2.77 1.64 2.48 5.36 7.07 5.56
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.37 4.48
Fixed Asset Turnover		 21.98 30.16 26.35 9.98 11.21 14.39 33.63 44.09 64.70 96.75
Accounts Payable Turnover		 0.06 0.10 0.09 0.04 0.06 0.09 0.14 0.24 0.26 0.29
Days Sales Outstanding (DSO)		 46.90 25.97 21.29 12.64 131.84 222.76 146.99 68.05 51.64 65.61
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 57.28 81.49
Days Payable Outstanding (DPO)		 6,289.55 3,552.54 3,929.89 8,393.63 5,996.90 3,849.46 2,564.05 1,546.91 1,399.26 1,258.97
Cash Conversion Cycle (CCC)		 -6,242.65 -3,526.57 -3,908.59 -8,380.99 -5,865.06 -3,626.69 -2,417.06 -1,478.87 -1,290.35 -1,111.87
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -4.75 -5.06 -3.61 -6.21 -3.72 -1.27 6.62 -5.29 -11 2.00
Invested Capital Turnover		 -3.44 -5.09 -5.28 -2.28 -3.39 -5.51 28.24 -14.50 -17.90 496.48
Increase / (Decrease) in Invested Capital		 -0.09 0.02 3.32 -1.45 1.02 3.80 10 0.93 -7.04 3.27
Enterprise Value (EV)		 249 193 159 330 362 472 935 772 1,003 1,894
Market Capitalization		 456 391 336 484 580 670 1,203 1,027 1,251 2,117
Book Value per Share		 $7.60 $7.23 $6.49 $5.51 $6.55 $5.95 $7.80 $6.68 $6.24 $5.87
Tangible Book Value per Share		 $7.60 $7.23 $6.49 $5.51 $6.43 $5.83 $7.69 $6.58 $6.02 $5.66
Total Capital		 222 212 198 172 243 227 305 324 309 296
Total Debt		 19 19 25 25 30 30 30 72 72 72
Total Long-Term Debt		 19 19 25 25 30 30 30 72 72 72
Net Debt		 -207 -198 -177 -154 -217 -198 -269 -255 -248 -223
Capital Expenditures (CapEx)		 0.10 0.13 0.34 0.79 0.38 0.00 0.17 1.04 0.28 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.77 -7.08 -5.83 -9.52 -11 -8.25 -0.33 -13 -26 -15
Debt-free Net Working Capital (DFNWC)		 220 210 195 169 236 219 298 311 291 276
Net Working Capital (NWC)		 220 210 195 169 236 219 298 311 291 276
Net Nonoperating Expense (NNE)		 6.48 3.06 5.95 8.45 10 11 9.35 9.98 5.81 6.02
Net Nonoperating Obligations (NNO)		 -207 -198 -177 -154 -217 -198 -269 -258 -248 -223
Total Depreciation and Amortization (D&A)		 0.13 -1.08 -1.30 -0.79 -0.18 0.37 0.09 -0.96 -0.73 -0.91
Debt-free, Cash-free Net Working Capital to Revenue		 -41.89% -27.42% -20.98% -76.14% -75.55% -47.27% -0.77% -15.07% -19.83% -8.35%
Debt-free Net Working Capital to Revenue		 1,360.68% 813.24% 703.43% 1,349.69% 1,642.39% 1,256.35% 700.63% 373.04% 224.69% 150.91%
Net Working Capital to Revenue		 1,360.68% 813.24% 703.43% 1,349.69% 1,642.39% 1,256.35% 700.63% 373.04% 224.69% 150.91%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.84) ($0.46) ($0.88) ($1.17) ($1.28) ($1.29) ($1.01) ($0.88) ($0.61) ($0.57)
Adjusted Weighted Average Basic Shares Outstanding		 26.66M 24.62M 26.74M 26.82M 30.62M 29.38M 35.30M 37.82M 38.38M 37.60M
Adjusted Diluted Earnings per Share		 ($0.84) ($0.46) ($0.88) ($1.17) ($1.28) ($1.29) ($1.01) ($0.88) ($0.61) ($0.57)
Adjusted Weighted Average Diluted Shares Outstanding		 26.66M 24.62M 26.74M 26.82M 30.62M 29.38M 35.30M 37.82M 38.38M 37.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 26.67M 26.73M 26.80M 32.62M 33.10M 34.22M 37.78M 38.04M 38.23M 38.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -11 -17 -23 -29 -31 -26 -23 -18 -17
Normalized NOPAT Margin		 0.00% -105.43% -698.66% 0.00% -1,531.51% -237.96% -95.53% -57.12% -36.60% -25.74%
Pre Tax Income Margin		 0.00% -135.99% -936.76% 0.00% -2,092.36% -320.45% -129.39% -81.57% -48.67% -34.80%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -36.25 -21.29 -36.59 -40.29 -47.94 -44.38 -38.52 -8.23 -10.26 -10.57
NOPAT to Interest Expense		 -25.33 -14.93 -25.54 -28.19 -33.40 -31.46 -26.84 -5.75 -7.20 -7.39
EBIT Less CapEx to Interest Expense		 -36.40 -21.47 -37.09 -41.25 -48.37 -44.38 -38.70 -8.49 -10.38 -10.61
NOPAT Less CapEx to Interest Expense		 -25.48 -15.11 -26.03 -29.16 -33.83 -31.46 -27.01 -6.01 -7.32 -7.43
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Tarsus Pharmaceuticals' Financials

When does Tarsus Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Tarsus Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Tarsus Pharmaceuticals' net income changed over the last 5 years?

Tarsus Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$115.55 million in 2024, rising from -$4.67 million in 2019. The previous period was -$135.89 million in 2023.

What is Tarsus Pharmaceuticals's operating income?
Tarsus Pharmaceuticals's total operating income in 2024 was -$120.57 million, based on the following breakdown:
  • Total Gross Profit: $170.13 million
  • Total Operating Expenses: $290.70 million
How has Tarsus Pharmaceuticals revenue changed over the last 5 years?

Over the last 5 years, Tarsus Pharmaceuticals' total revenue changed from $0.00 in 2019 to $182.95 million in 2024, a change of 18,295,300,000.0%.

How much debt does Tarsus Pharmaceuticals have?

Tarsus Pharmaceuticals' total liabilities were at $152.46 million at the end of 2024, a 122.6% increase from 2023, and a 16,489.4% increase since 2019.

How much cash does Tarsus Pharmaceuticals have?

In the past 5 years, Tarsus Pharmaceuticals' cash and equivalents has ranged from $57.95 million in 2019 to $224.95 million in 2023, and is currently $94.82 million as of their latest financial filing in 2024.

How has Tarsus Pharmaceuticals' book value per share changed over the last 5 years?

Over the last 5 years, Tarsus Pharmaceuticals' book value per share changed from -2.54 in 2019 to 5.87 in 2024, a change of -331.1%.

Remove Ads

Related Companies

This page (NASDAQ:TARS) was last updated on 4/12/2025 by MarketBeat.com Staff
From Our Partners
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored
The real reason gold is soaring (and likely to continue)
Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...
Golden Portfolio | Sponsored
Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...
True Market Insiders | Sponsored
This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...
Colonial Metals | Sponsored
BITCOIN
Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....
Awesomely, LLC | Sponsored
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...
Timothy Sykes | Sponsored
DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...
Altimetry | Sponsored
Millions of Americans are going to be shocked as soon as May 31
Worried About the Market? See This Immediately... While CNBC and the Wall Street Journal are focused on Lib...
Stansberry Research | Sponsored